Assessment of Serum Uric Acid Levels According to Sex and Stage for Patients with Alzheimer-type Dementia

Tamer Yazar; Hülya Olgun Yazar

doi:10.4274/tnd.2019.85698

Tamer Yazar¹, Hülya Olgun Yazar²

¹Ordu State Hospital, Clinic of Neurology, Ordu, Turkey
²Ordu University Training and Research Hospital, Clinic of Neurology, Ordu, Turkey

Keywords: Alzheimer disease, dementia, oxidative stress, uric acid, sex

Abstract

Objective: The aim of this study was to identify serum uric acid (UA) concentrations according to disease stage in patients with Alzheimer-type dementia (AD), and to collect data related to the hypothesis that oxidative stress is effective on the etiopathogenesis and progression of disease stage.

Materials and Methods: The study was conducted with 180 patients who were categorized into disease stages in accordance with the Clinical Dementia Rating Scale (CDR) and 150 healthy individuals of the same age group. In our retrospective study, patients who showed more than one cognitive deficit and diagnosed with possible AD according to the diagnostic criteria of National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders Association were administered the CDR, Mini-Mental Test (MMSE), Geriatric Depression Rating Scale (GDRS), and individuals in the control group were administered the MMSE and GDRS. Venous blood samples for biochemical studies were collected after 12-14 hours of fasting in the patient and control groups.

Results: In patients diagnosed as having AD, it was found that there was a statistically significant increase in age and duration of disease parallel with the progression of disease stages, and a decrease in UA and albumin concentrations in both males and females (p<0.05).

Conclusion: Our study supports the hypothesis that the decrease detected in serum UA concentrations in parallel with the progression of disease stages is directly related to the pathogenesis of AD. For the identification of chronic progressive diseases such as AD and to take precautions, the identification of variations in easily accessible and low-cost parameters such as serum albumin and UA concentrations in the early stages becomes important. In future years, when neuroprotective and neuro-restorative treatment options are available, identification of serum UA values as a marker of disease progression and knowledge of the association between serum UA concentrations and disease stage in our data will guide and support research into disease etiology.